LY3541860 for Rheumatoid Arthritis

Recruiting at 20 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Eli Lilly and Company

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for adults with moderate to severe Rheumatoid Arthritis who haven't had enough improvement with at least one biologic or synthetic disease-modifying drug. Participants should be able to commit to a 50-week study period.

Inclusion Criteria

I have active joint inflammation in my hand or wrist.

I have been diagnosed with Rheumatoid Arthritis for at least 3 months.

I have active RA with 6 or more swollen and tender joints.

Exclusion Criteria

My kidney function is reduced, with an eGFR below 45 mL/min.

I currently have or recently had an infection.

I have received treatment targeting B-cells, like rituximab.

Treatment Details

Interventions

• LY3541860 (Monoclonal Antibodies)

Trial Overview The trial is testing LY3541860's effects on those with active Rheumatoid Arthritis. It includes a 6-week screening, a 24-week treatment phase, and a 20-week safety follow-up.

Participant Groups

Group I: LY3541860 Experimental Treatment 1 Intervention

LY3541860 will be administered intravenously (IV).

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University